-
1.发明授权Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds 失效使用FK 506和相关化合物治疗脓皮病和Sezary综合征的方法
公开(公告)号：US5348966A
公开(公告)日：1994-09-20
申请号：US155533
申请日：1993-11-22
申请人： Thomas E. Starzl , Satoru Todo
发明人： Thomas E. Starzl , Satoru Todo
IPC分类号： A61K31/445 , A61K31/33 , A61K31/40
CPC分类号： A61K31/445
摘要： Administration of FK506 or related macrolide compounds is effective for the treatment of pyoderma and Sezary's syndrome.
摘要翻译： FK506或相关大环内酯类化合物的施用对于治疗脓皮病和Sezary综合征是有效的。
-
2.发明授权Method for treating hepatic diseases and regenerating liver tissue using FK 506 and related compounds 失效使用FK 506和相关化合物治疗肝脏疾病和再生肝组织的方法
公开(公告)号：US5196437A
公开(公告)日：1993-03-23
申请号：US629028
申请日：1990-12-18
CPC分类号： A61K31/70 , Y10S514/838 , Y10S514/894
摘要： Macrolide compounds having the structure shown below ##STR1## wherein R.sup.1 is hydroxy or protected hydroxy, R.sup.2 is hydrogen, hydroxy or protected hydroxy, R.sup.3 is methyl, ethyl, propyl or allyl, R.sup.4 is hydroxy, methoxy or oxo, n is 1 or 2 and the symbol of a line and a dotted is a single bond or a double bond, provided that R.sup.2 is not protected hydroxy where R.sup.4 is hydroxy or oxo are used to treat hepatic disease and regenerate liver tissue by facilitating hypertrophy and hyperplasia of hepatocytes.
摘要翻译： 具有下述结构的大环内酯化合物（I）其中R1是羟基或被保护的羟基，R2是氢，羟基或被保护的羟基，R3是甲基，乙基，丙基或烯丙基，R4是羟基，甲氧基或氧代，n是 1或2，线和点的符号是单键或双键，条件是R2不是保护的羟基，其中R4是羟基或氧代，用于治疗肝脏疾病并通过促进肥大和增生来再生肝组织 肝细胞。
-
公开(公告)号：US5607844A
公开(公告)日：1997-03-04
申请号：US367968
申请日：1995-01-03
摘要： Full-length cDNA clones have been isolated encoding purified augmenter of liver regeneration (ALR) polypeptides prepared from the cytosol of livers from weanling rats and from humans. The full-length clone from the rat is a 1226 bp cDNA containing an 81 bp 5'-untranslated region, a 594 bp coding region and a 551 bp 3'-untranslated region. The coding region encodes three proteins with estimated molecular weights of 15,081, 20,193 and 22,835. The full-length clone from the human consists of a 727 bp cDNA containing a 4 bp 5'-untranslated region, a 615 bp coding region and a 108 bp 3'-untranslated region, including the termination codon TAG and the poly (A) region. The 615 bp coding region encodes four proteins, human ALR-V1, ALR-V2, ALR-V3 and ALR, having estimated molecular weights of 23,448, 20,834, 20,703 and 15,028, respectively.
摘要翻译： 已经分离了全长cDNA克隆，编码从断奶大鼠和人的肝细胞溶质制备的肝再生（ALR）多肽的纯化增强子。 来自大鼠的全长克隆是含有81bp 5'-非翻译区，594bp编码区和551bp 3'非翻译区的1226bp cDNA。 编码区编码三种估计分子量为15,081,20,193和22,835的蛋白质。 来自人的全长克隆由含有4bp 5'-非翻译区，615bp编码区和108bp 3'非翻译区的727bp cDNA组成，包括终止密码子TAG和聚（A） 地区。 615bp编码区编码四种蛋白质，人类ALR-V1，ALR-V2，ALR-V3和ALR，分别估计分子量为23,448,20,834,20,703和15,028。
-
公开(公告)号：US5480797A
公开(公告)日：1996-01-02
申请号：US197496
申请日：1994-02-16
摘要： A full-length cDNA clone has been isolated encoding a purified augmenter of liver regeneration (ALR) polypeptide prepared from the cytosol of livers from weanling rats. The 1.2 kb cDNA includes a 299 bp 5'-untranslated region, a 375 bp coding region and a 551 bp 3'-untranslated region. The cDNA encodes a protein consisting of 125 amino acids. The molecular weight of ALR calculated from the cDNA was 15,081 which is consistent with the size estimated by SDS-PAGE under reducing conditions. The molecular weight of the purified native ALR estimated by SDS-PAGE under non-reducing conditions is about 30,000, apparently with a homodimer structure. The recombinant ALR produced by expression of the cDNA in cultured cells was tested in vivo in the canine Eck's fistula model and found to have a potency equivalent to the purified native ALR. The most obvious immediate clinical use for the augmenter of liver regeneration is in the treatment of hepatic failure.
摘要翻译： 已经分离了全长cDNA克隆，其编码从断奶大鼠的肝细胞质中制备的纯化的肝再生增强子（ALR）多肽。 1.2kb cDNA包括299bp的5'非翻译区，375bp的编码区和551bp的3'非翻译区。 cDNA编码由125个氨基酸组成的蛋白质。 从cDNA计算的ALR的分子量为15,081，这与在还原条件下通过SDS-PAGE估计的大小一致。 在非还原条件下通过SDS-PAGE估计的纯化天然ALR的分子量约为30,000，显然具有同二聚体结构。 在犬Eck的瘘模型中体内测试了通过在培养细胞中表达cDNA产生的重组ALR，并发现其具有与纯化的天然ALR相当的效力。 用于肝再生增强剂的最明显的临床应用是治疗肝衰竭。
-
5.发明授权Composition containing immature mammalian dendritic cells for enhancing tolerogenicity to foreign graft 失效含有不成熟哺乳动物树突状细胞以增强对外来移植物的耐受性的组合物公开(公告)号：US06224859B1
公开(公告)日：2001-05-01
申请号：US09064829
申请日：1998-04-23
IPC分类号： A01N6300
CPC分类号： A61K39/001 , A61K38/00 , A61K2035/122 , C12N5/064 , C12N2501/22
摘要： A novel transplantation method for enhancing tolerogenicity in a host mammal to a transplant graft specimen from a donor mammal is disclosed. According to this method, immature mammalian dendritic cells propagated in the presence of a cytokine are administered to the host mammal in advance of transplantation. Tolerogenicity is enhanced in the host mammal when the immature mammalian dendritic cells concentrate in T-dependent regions of secondary lymphoid tissue of the host mammal, where the expression of major histocompatibility complex class II antigen by the immature mammalian dendritic cells is upregulated. Also disclosed is a novel method of effecting the maturation of immature dendritic cells in the presence of a cytokine and an extracellular matrix protein. These mature mammalian dendritic cells, which upregulate the expression of major histocompatibility complex class II antigen, can then be used to enhance the immune response of a host mammal.
摘要翻译： 公开了一种用于增强宿主哺乳动物对来自供体哺乳动物的移植移植物标本的耐受性的新型移植方法。 根据该方法，在移植前向宿主哺乳动物施用在细胞因子存在下繁殖的未成熟哺乳动物树突状细胞。 当未成熟的哺乳动物树突状细胞集中在宿主哺乳动物的次级淋巴组织的T依赖区域中时，宿主哺乳动物的耐受性增强，其中未成熟哺乳动物树突状细胞的主要组织相容性复合物II类抗原的表达被上调。 还公开了一种在细胞因子和细胞外基质蛋白的存在下实现未成熟树突状细胞的成熟的新方法。 这些成熟的哺乳动物树突细胞，其上调主要组织相容性复合物II类抗原的表达，然后可以用于增强宿主哺乳动物的免疫应答。
-
公开(公告)号：US5871728A
公开(公告)日：1999-02-16
申请号：US414461
申请日：1995-03-31
CPC分类号： A61K39/001 , C12N5/064 , A61K2035/122 , A61K38/00 , C12N2501/22
摘要： A novel transplantation method for enhancing tolerogenicity in a host mammal to a transplant graft specimen from a donor mammal is disclosed. According to this method, immature mammalian dendritic cells propagated in the presence of a cytokine are administered to the host mammal in advance of transplantation. Tolerogenicity is enhanced in the host mammal when the immature mammalian dendritic cells concentrate in T-dependent regions of secondary lymphoid tissue of the host mammal, where the expression of major histocompatibility complex class II antigen by the immature mammalian dendritic cells is upregulated. Also disclosed is a novel method of effecting the maturation of immature dendritic cells in the presence of a cytokine and an extracellular matrix protein. These mature mammalian dendritic cells, which upregulate the expression of major histocompatibility complex class II antigen, can then be used to enhance the immune response of a host mammal.
摘要翻译： 公开了一种用于增强宿主哺乳动物对来自供体哺乳动物的移植移植物标本的耐受性的新型移植方法。 根据该方法，在移植前向宿主哺乳动物施用在细胞因子存在下繁殖的未成熟哺乳动物树突状细胞。 当未成熟的哺乳动物树突状细胞集中在宿主哺乳动物的次级淋巴组织的T依赖区域中时，宿主哺乳动物的耐受性增强，其中未成熟哺乳动物树突状细胞的主要组织相容性复合物II类抗原的表达被上调。 还公开了一种在细胞因子和细胞外基质蛋白的存在下实现未成熟树突状细胞的成熟的新方法。 这些成熟的哺乳动物树突细胞，其上调主要组织相容性复合物II类抗原的表达，然后可以用于增强宿主哺乳动物的免疫应答。
-
公开(公告)号：US5811397A
公开(公告)日：1998-09-22
申请号：US665484
申请日：1996-06-12
IPC分类号： A61K38/00 , C07K14/47 , C12N15/12 , A61K38/18 , C07K14/475
摘要： Full-length cDNA clones have been isolated encoding purified augmenter of liver regeneration (ALR) polypeptides prepared from the cytosol of livers from weanling rats and from humans. The full-length clone from the rat is a 1226 bp cDNA containing an 81 bp 5'-untranslated region, a 594 bp coding region and a 551 bp 3'-untranslated region. The coding region encodes three proteins with estimated molecular weights of 15,081, 20,193 and 22,835. The full-length clone from the human consists of a 727 bp cDNA containing a 4 bp 5'-untranslated region, a 615 bp coding region and a 108 bp 3'-untranslated region, including the termination codon TAG and the poly (A) region. The 615 bp coding region encodes four proteins, human ALR-V1, ALR-V2, ALR-V3 and ALR, having estimated molecular weights of 23,448, 20,834, 20,703 and 15,028, respectively.
摘要翻译： 已经分离了全长cDNA克隆，编码从断奶大鼠和人的肝细胞溶质制备的肝再生（ALR）多肽的纯化增强子。 来自大鼠的全长克隆是含有81bp 5'-非翻译区，594bp编码区和551bp 3'非翻译区的1226bp cDNA。 编码区编码三种估计分子量为15,081,20,193和22,835的蛋白质。 来自人的全长克隆由含有4bp 5'-非翻译区，615bp编码区和108bp 3'非翻译区的727bp cDNA组成，包括终止密码子TAG和聚（A） 地区。 615bp编码区编码四种蛋白质，人类ALR-V1，ALR-V2，ALR-V3和ALR，分别估计分子量为23,448,20,834,20,703和15,028。
-
公开(公告)号：US5550037A
公开(公告)日：1996-08-27
申请号：US275370
申请日：1994-07-15
摘要： Full-length cDNA clones have been isolated encoding purified augmenter of liver regeneration (ALR) polypeptides prepared from the cytosol of livers from human and from weanling rats. The 0.5 kb human ALR cDNA includes a 33 bp 5'-untranslated region, a 375 bp coding region and a 107 bp 3'-untranslated region. The cDNA encodes a protein consisting of 125 amino acids. The molecular weight of human ALR calculated from the cDNA was 15,028. A comparison of the sequences for the human ALR with those of the rat ALR shows 71% homology at the nucleotide level and 86% homology at the amino acid level. The most obvious immediate clinical use for the augmenter of liver regeneration is in the treatment of hepatic failure.
摘要翻译： 已经分离了全长cDNA克隆，其编码从人类和断奶大鼠的肝细胞溶质制备的肝再生（ALR）多肽的纯化增强子。 0.5kb的人类ALR cDNA包括33bp的5'非翻译区，375bp的编码区和107bp的3'非翻译区。 cDNA编码由125个氨基酸组成的蛋白质。 从cDNA计算的人ALR的分子量为15,028。 人类ALR序列与大鼠ALR的序列比较显示核苷酸水平为71％同源性，氨基酸水平为86％同源性。 用于肝再生增强剂的最明显的临床应用是治疗肝衰竭。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.028 秒)